H
HeartFlow
Biotech & Life Sciences · Redwood City, United States · Founded 2007 · IPO 2025
A non-invasive personalized cardiac test, physicians are able to make better care decisions for their patients with suspected coronary artery disease MoreLess
HeartFlow is a health technology startup that operates in the cardiovascular care market. The company has developed a non-invasive cardiac test that provides detailed visualization of a patient's coronary arteries. This innovative technology assists physicians in creating more effective treatment plans for their patients, thereby making cardiovascular care safer and easier.
The company's primary clients are physicians and healthcare providers who are looking for safer, more efficient ways to diagnose and treat heart disease. HeartFlow's technology eliminates the need for invasive procedures, reducing both the risk to patients and the cost to healthcare providers.
HeartFlow's business model is based on the sale of its proprietary technology. The company's HeartFlow Analysis, which includes the FFRCT Analysis, RoadMap Analysis, Plaque Analysis, and HeartFlow Planner, has received FDA Clearance in the United States and is commercially available in the United States and the United Kingdom. It is also approved in Japan and Canada.
The company generates revenue by selling its technology to healthcare providers. It also likely earns income from ongoing service and maintenance contracts, as well as from updates and improvements to its technology.
In summary, HeartFlow is a health tech startup that has developed a non-invasive cardiac test to assist physicians in diagnosing and treating heart disease. The company operates in the cardiovascular care market and generates revenue from the sale of its technology and related services.
Keywords: Health Technology, Cardiovascular Care, Non-Invasive Cardiac Test, Coronary Arteries Visualization, Safer Diagnosis, Treatment Planning, FDA Clearance, Commercial Availability, Revenue Generation, Proprietary Technology.
Talent graph
HeartFlow's talent
Source: Dealroom Talent Intelligence.
Global footprint
Where HeartFlow has talent and traffic
team presence
across markets
Patent intelligence
$229M patent portfolio · 88 active families
Where HeartFlow concentrates vs peers
Each axis is a top-10 topic across HeartFlow and its closest peers. #1 = 100, #10 = 10, absent = 0.
Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.
Market sentiment
What the market is saying about HeartFlow
An AI-synthesized read of the highest-engagement posts about HeartFlow on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See HeartFlow on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.











